In a Phase I study involving HLA-DPB1*0401-restricted T-cell receptors (TCRs) that was designed to specifically recognise MAGE-A3 antigen, complete remission was seen in a patient with metastatic cervical cancer, and partial remission was seen in 3 patients [110]. Here, MAGEA3 is linked to cervical cancer.